(Press-News.org) BOSTON—Women experiencing moderate-to-severe vasomotor symptoms face a three times greater risk for metabolic-dysfunction-associated steatotic liver disease (MASLD) compared to those with mild symptom severity, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Vasomotor symptoms include hot flashes or night sweats—symptoms that have become synonymous with menopause.
“This research is significant as it contributes to understanding the link between vasomotor symptoms and cardiometabolic risk factors,” said Eleni Armeni, M.D., M.Sc., Ph.D., a research fellow at the Second Department of Obstetrics and Gynecology, at Aretaieio Hospital National and Kapodistrian University of Athens, in Athens, Greece. “It is crucial for the general public because it emphasizes how hot flashes and night sweats can signal an increased risk for heart and metabolic issues.”
MASLD is also known as non-alcoholic fatty liver disease (NAFLD). In this cross-sectional study, researchers sought to analyze the likelihood of someone developing MASLD related to menopause and the potential link with vasomotor symptoms.
“Women experiencing these symptoms should consult a health care professional to address the symptoms and assess their cardiovascular health,” Armeni said. “Previously, vasomotor symptoms were primarily seen as indicators of estrogen deficiency, but this study suggests broader implications for cardiovascular health related to this hormonal imbalance.”
Armeni and colleagues evaluated 106 peri- and postmenopausal women treated in an outpatient menopause clinic. They estimated steatotic liver disease (SLD) to determine the risk of the fatty liver index. The researchers accounted for age, exercise, alcohol, smoking, a history of menstrual irregularity, and hormone replacement therapy use.
The results showed that 42 women with moderate-to-severe vasomotor symptoms had a three times higher risk for MASLD compared with 64 women who had mild symptom severity. That risk was 9.3 times higher when they limited the sample to those who experienced symptoms within five years after the menopausal transition.
“We hope these findings will encourage health care providers to offer comprehensive care to peri- and postmenopausal women, going beyond discussions solely focused on hormone replacement therapy,” Armeni said.
Armeni is scheduled to speak at the Society's reproductive health news conference at 11 a.m. Eastern June 2. Register to view the livestream at endomediastream.com.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
Hot flashes in menopausal women may signal increased risk for heart and metabolic issues
2024-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Revolutionizing robotics: Integrating actuation and sensing for smarter soft robots
2024-06-02
The world of robotics is witnessing a transformative shift with the rise of soft robotics, which offers unparalleled flexibility and adaptability in various applications, from medical interventions to intricate rescue operations. A groundbreaking review article by Zhou et al. published in Cyborg Bionic Systems in 2024, sheds light on this evolution, highlighting the crucial integration of actuation and sensing technologies that pave the way for truly intelligent soft robots.
Soft robots, unlike their rigid counterparts, are made from materials that mimic the mechanical properties of living tissues, allowing them to move and adapt with a life-like grace. This capability makes ...
Almost 20% of breast cancer survivors may experience excess weight gain
2024-06-02
BOSTON—Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
Factors associated with more than 10% weight gain included a lower weight, younger age, and more advanced cancer stage at cancer diagnosis; hormone-positive breast cancer; mutations of the BRCA2 gene; undergoing more aggressive breast surgery; and the use of chemotherapy and endocrine therapy, the study found.
“Weight ...
Immunotherapy significantly increases the number of patients free from bowel cancer
2024-06-02
An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
The findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, are interim results from the NEOPRISM-CRC phase II clinical trial assessing whether the immunotherapy drug pembrolizumab can improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. The ...
Stepped palliative care for patients with advanced lung cancer
2024-06-02
About The Study: A stepped-care model, with palliative care visits occurring only at key points in patients’ cancer trajectories and using a decrement in quality of life to trigger more intensive palliative care exposure, resulted in fewer palliative care visits without diminishing the benefits for patients’ quality of life. While stepped palliative care was associated with fewer days in hospice, it is a more scalable way to deliver early palliative care to enhance patient-reported outcomes.
Quote from corresponding author Jennifer S. Temel, M.D.:
“This study demonstrates that early palliative ...
Trial reveals benefits of ‘stepped’ palliative care for patients with advanced lung cancer
2024-06-02
BOSTON – A new study led by investigators from Mass General Cancer Center, a founding member of the Mass General Brigham healthcare system, reveals the effectiveness of more scalable ways of delivering palliative care to patients with advanced lung cancer. The findings were highlighted at the American Society of Clinical Oncology’s annual meeting and are published in JAMA.
The study, led by Jennifer S. Temel, MD of the Mass General Cancer Center, assessed the effectiveness of stepped palliative care, in which all patients receive palliative care for their condition, but with a minimum of required contact with a specialty-trained clinician. ...
Socioeconomic status influences genetic risk for many complex diseases
2024-06-02
Berlin, Germany: Differences in socioeconomic status (SES) are known to be linked to differences in the risk of developing disease. While people with lower SES are more likely to develop complex diseases such as diabetes and cardiovascular disease, those with a higher SES are at increased risk of developing certain types of cancer. Using biobank and national register data, researchers from Finland have now found that people with lower SES (educational achievement and occupation) have a greater genetic susceptibility to develop many other complex diseases such as rheumatoid arthritis, lung cancer, depression, and alcohol ...
ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies
2024-06-01
CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. For those whose cancers return or become resistant after CAR T cell therapy, the prognosis is poor, with few options left.
A new “armored” form of CAR T cell therapy, developed by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University ...
People with well-controlled, long-duration type 1 diabetes may still face high risk of heart disease
2024-06-01
BOSTON—People who have had type 1 diabetes for more than 50 years without kidney complications may still be at substantial risk for heart disease, despite excellent control of blood pressure, cholesterol and blood sugar levels, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Heart disease is a major cause of death in people with type 1 diabetes, especially in those who develop kidney complications from diabetes.
“As people with type 1 diabetes live longer due to improved medical care, a substantial proportion of these patients survive without kidney complications, but are still at high risk for heart ...
GLP-1 medications for type 2 diabetes and obesity may lower risk of acute pancreatitis
2024-06-01
BOSTON—Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Doctors have been cautious about prescribing these medications in patients with a history of pancreatitis due to the potential risk of worsening the condition – a warning that is included in prescribing information, said lead researcher Mahmoud Nassar, M.D., Ph.D., Department of Medicine ...
Anti-obesity medication tirzepatide remains effective even for those with diabetes and other complications
2024-06-01
BOSTON—Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Obesity causes or worsens over 200 diseases. It has been widely believed that when patients suffer multiple medical problems, they are not able to lose as much weight as those without medical issues. The new study, funded by tirzepatide maker Eli Lilly Inc., was designed to see if having more obesity-associated ...